Metabolomics Analysis of Triple Negative Breast Cancer (BCa) Cell Lines
Ontology highlight
ABSTRACT: We used untargeted metabolomic profiling to distinguish this form of BCa from estrogen receptor positive (ER+) subtypes (+/- HER2/neu) and determine that may explain why a commonly used chemotherapeutic, paclitaxel, is generally ineffective at eliciting long-term cytotoxic and/or cytostatic responses in cell line models of TNBC. This metabolomics study used broad spectrum 1H NMR to compare Luminal A (BT474, MCF-7) and triple-negative (MDA-MB-231, MDA-MB-468) BCa cell lines, to determine differences in the two subtypes as well as distinguish therapeutic treatment responses for identifying new targets for drug discovery.
ORGANISM(S): Human Homo Sapiens
TISSUE(S): Cells
DISEASE(S): Cancer
SUBMITTER: Susan Sumner
PROVIDER: ST000442 | MetabolomicsWorkbench | Tue Aug 02 00:00:00 BST 2016
REPOSITORIES: MetabolomicsWorkbench
ACCESS DATA